tak-816
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01379846)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Cannabinoid CB2 receptorANTAGONIST
CNR2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tak-816
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02074345 | Phase 3 | Mar 1, 2014 | Takeda |
| NCT01379846 | Phase 3 | Jun 1, 2011 | Takeda |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 2 | 2 | 1 | 2011 |
1 organizations
Page 1 / 1